OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MDNYSE67

Pediatrix Medical Group, Inc.

Healthcare Facilities & ServicesVerified

Capital Structure and Liquidity Pediatrix has a debt-to-equity ratio of 0.66, indicating a moderate level of leverage. The company's current ratio of 1.66 suggests it has sufficient short-term assets to cover its short-term liabilities. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. ### Profitability and Returns The company's return on equity (ROE) is 19.1%, and its return on assets (ROA) is 7.36%. These figures are strong indicators of efficient use of equity and assets, respectively. The operating income of $208.81 million and net income of $165.39 million for FY2025 reflect solid profitability. These metrics are in line with the industry's preferred metrics for healthcare providers. ### Segments and Geographic Exposure Pediatrix operates primarily in the United States, with a focus on hospital-based care. The company's services are concentrated in obstetrics, maternal-fetal medicine, and neonatology. The financial data does not provide specific geographic revenue breakdowns, but the company's operations are largely domestic. ### Growth Trajectory The company's revenue for the nine months ended September 30, 2025, was $1.42 billion, a decrease from $1.51 billion in the same period in 2024. The net income for the nine months ended September 30, 2025, was $131.71 million, compared to a net loss of $129.55 million in the same period in 2024. This indicates a significant improvement in profitability, although revenue has declined. ### Risk Factors The company faces medium liquidity risk, as noted in the risk assessment. The risk of dilution is low, but the company has a revolving credit facility and long-term debt, which could impact its financial flexibility. The risk assessment also highlights the potential for restructuring and transformational expenses, which could affect future profitability. ### Recent Events Recent filings indicate that the company has been involved in restructuring and transformational activities, including the impairment of goodwill and long-lived assets. The company also reported a net gain on investments in divested businesses, which positively impacted its financial results. Additionally, the company has been repurchasing common stock, which could signal confidence in its future performance.

30-day price · MD(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyPediatrix Medical Group, Inc.
ExchangeNYSE
TickerMD
CIK0000893949
SICServices-Hospitals
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Pediatrix Medical Group, Inc. provides physician services in newborn, maternal-fetal, and pediatric subspecialty care, primarily through hospital-based neonatal intensive care units (NICUs) and affiliated clinicians.

Classification. Pediatrix is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector and the Healthcare Facilities & Services industry, with a classification confidence of 0.92.

### Capital Structure and Liquidity Pediatrix has a debt-to-equity ratio of 0.66, indicating a moderate level of leverage. The company's current ratio of 1.66 suggests it has sufficient short-term assets to cover its short-term liabilities. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. ### Profitability and Returns The company's return on equity (ROE) is 19.1%, and its return on assets (ROA) is 7.36%. These figures are strong indicators of efficient use of equity and assets, respectively. The operating income of $208.81 million and net income of $165.39 million for FY2025 reflect solid profitability. These metrics are in line with the industry's preferred metrics for healthcare providers. ### Segments and Geographic Exposure Pediatrix operates primarily in the United States, with a focus on hospital-based care. The company's services are concentrated in obstetrics, maternal-fetal medicine, and neonatology. The financial data does not provide specific geographic revenue breakdowns, but the company's operations are largely domestic. ### Growth Trajectory The company's revenue for the nine months ended September 30, 2025, was $1.42 billion, a decrease from $1.51 billion in the same period in 2024. The net income for the nine months ended September 30, 2025, was $131.71 million, compared to a net loss of $129.55 million in the same period in 2024. This indicates a significant improvement in profitability, although revenue has declined. ### Risk Factors The company faces medium liquidity risk, as noted in the risk assessment. The risk of dilution is low, but the company has a revolving credit facility and long-term debt, which could impact its financial flexibility. The risk assessment also highlights the potential for restructuring and transformational expenses, which could affect future profitability. ### Recent Events Recent filings indicate that the company has been involved in restructuring and transformational activities, including the impairment of goodwill and long-lived assets. The company also reported a net gain on investments in divested businesses, which positively impacted its financial results. Additionally, the company has been repurchasing common stock, which could signal confidence in its future performance.
Key takeaways
  • Pediatrix has a strong return on equity (19.1%) and return on assets (7.36%), indicating efficient use of capital.
  • The company's liquidity position is moderate, with a current ratio of 1.66, but net cash is negative after subtracting total debt.
  • Pediatrix's profitability has improved significantly, with a net income of $165.39 million for FY2025.
  • The company's operations are primarily domestic, with a focus on hospital-based neonatal and maternal-fetal care.
  • Recent restructuring and transformational activities have impacted the company's financial results, including goodwill and long-lived asset impairments.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue
Gross profit
Operating income$208.8M
Net income$165.4M
R&D
SG&A$240.8M
D&A$21.8M
SBC$18.0M
Operating cash flow$271.1M
CapEx
Free cash flow
Total assets$2.25B
Total liabilities$1.38B
Total equity$865.9M
Cash & equivalents$375.2M
Long-term debt$570.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$208.8M$165.4M
FY2024-$68.7M-$99.1M
FY2025-$68.7M-$99.1M
FY2023$7.3M-$60.4M
FY2024$7.3M-$60.4M
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2023
FY2024
PeriodAssetsEquityCashDebt
FY2025$2.25B$865.9M$375.2M
FY2024$2.15B$764.9M$229.9M
FY2025$2.15B$764.9M$229.9M
FY2023$2.22B$849.1M$73.3M
FY2024$2.22B$849.1M$73.3M
PeriodOCFCapExFCFSBC
FY2025$271.1M$18.0M
FY2024$206.6M$11.9M
FY2025$206.6M$11.9M
FY2023$137.3M$12.3M
FY2024$137.3M$12.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$160.0M$131.7M
Q2 2025$92.0M$60.0M
Q3 2025$39.3M
Q1 2025$32.1M$20.7M
PeriodGross %Op %Net %FCF %
Q3 2025
Q2 2025
Q3 2025
Q1 2025
PeriodAssetsEquityCashDebt
Q3 2025$2.20B$890.7M$340.1M
Q2 2025$2.10B$833.8M$224.7M
Q3 2025$833.8M
Q1 2025$1.99B$789.2M$99.0M
PeriodOCFCapExFCFSBC
Q3 2025$157.0M$12.7M
Q2 2025$19.7M$7.5M
Q3 2025
Q1 2025-$117.5M$3.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$411.7M
Net cash-$195.3M
Current ratio1.7
Debt/Equity0.7
ROA7.4%
ROE19.1%
Cash conversion1.6%
CapEx/Revenue
SBC/Revenue
Asset intensity0.0
Dilution ratio2.8%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricMDActivity
Op margin11.5% medp25 9.9% · p75 15.0%
Net margin8.6% medp25 6.3% · p75 12.4%
Gross margin28.8% medp25 28.8% · p75 28.8%
CapEx / revenue4.2% medp25 3.8% · p75 4.2%
Debt / equity66.0%71.3% medp25 60.7% · p75 71.3%below median
Observations
IR observations
market data ESG controversies score100.0
market data ESG governance pillar86.4
market data ESG social pillar47.0
market data insider trading score4.0
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
SEC filingstype companyfacts · CIK 0000893949 · 532 us-gaap concepts
2026-05-01 16:52 UTC#5bb63d72
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 16:55 UTCJob: e06ae9cf